Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.9196
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 36.42 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 5.26 | Oscillator | Buy |
| Williams %R (14) | -100.00 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.07 (Hist -0.03) | Oscillator | Strong Sell |
| Average Directional Index (14) | 22.92 (+DI 24.1 / -DI 24.0) | Trend | Buy |
| EMA 20 | 1.13 | MA | Strong Sell |
| SMA 20 | 1.21 | MA | Strong Sell |
| EMA 50 | 1.18 | MA | Strong Sell |
| SMA 50 | 1.16 | MA | Strong Sell |
| SMA 200 | 1.37 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 25, 26 | Vnook Stella | director | A-Award | 84,033 | — |
| Sep 25, 26 | Posner Brian M | director | A-Award | 84,033 | — |
| Sep 25, 26 | Menawat Arun Swarup | director | A-Award | 126,050 | — |
| Sep 8, 26 | Paz Jessica Lucia | officer: Chief Accounting Officer | 50,000 @ $1.11 | $55.50K | |
| Aug 12, 24 | Lipschitz Gregory | director, officer: Interim CEO | 0 | — | |
| Mar 10, 26 | Decaprio David | director, officer: President and COO | A-Award | 44,872 | — |
| Mar 10, 26 | Lipschitz Gregory | director, officer: Chief Executive Officer | A-Award | 65,988 | — |
| Oct 28, 25 | Menawat Arun Swarup | director | A-Award | 73,892 | — |
SEC EDGAR filings · last 12 months
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | AIFF | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.4x | -62.5x · sector 44.2x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 1.3x | -24.0x | Discount |
| Price / Sales | 8.0x | 7354.8x | Discount |
| EV / EBITDA | -0.6x | -71.7x | Discount |
| Return on equity | -90.2% | — | Weak |
| Gross margin | 44.6% | 58.9% | Below hist. |
| Debt / Equity | 0.00 | -0.49 | Conservative |
| Piotroski / Altman Z | 3/9 | Z -6.59 | Distress |
Discounted cash flow model
Stock news · updated daily
Definitive Healthcare (NASDAQ: DH - Get Free Report) and Firefly Neuroscience (NASDAQ: AIFF - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation. Profitability This table compares Definitive Healthcare and
Firefly Neuroscience Inc. (NASDAQ:AIFF), an artificial intelligence company advancing precision neuroscience, partnered with NeuroSigma, Inc., a bioelectronic medical device firm, to expand clinician awareness and access to the Monarch eTNS System across the U.S.
– Partnership will introduce NeuroSigma's second-generation Monarch eTNS ® System to Firefly's nationwide network of Evoke™ clinicians –
– This integration of Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial's August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country's largest brain medicine clinical network –
Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and Firefly Neuroscience (NASDAQ: AIFF - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings. Insider and Institutional Ownership 5.0% of Firefly Neuroscience
KENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its U.S. Food and Drug Administration (“FDA”) 510(k)-cleared, AI-powered EEG/ERP platform, Evoke™.
– FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax, late last week –
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | — | -0.10 | — | $514.0K |
| Jun 30, 2026 | — | -0.13 | — | $485.0K |
| May 12, 2026 | — | -0.13 | — | $412.0K |
| Nov 12, 2025 | — | -0.20 | — | $388.0K |
| Aug 13, 2025 | — | -0.14 | — | $299.0K |
| May 14, 2025 | — | -1.30 | — | $43.00K |